iCAD, Inc. (Nasdaq: ICAD), a leading provider of advanced image analysis
and radiation therapy solutions for the early identification and
treatment of cancer, today announced at the 31st Annual Miami
Breast Cancer Conference that more than 1,000 early stage breast cancer
patients have been treated with Intraoperative Radiation Therapy (IORT)
using the Xoft®
Axxent® Electronic Brachytherapy System®. With
IORT, a full course of radiation therapy is delivered to the patient in
the operating room immediately following lumpectomy, replacing six to
eight weeks of daily traditional radiation.
“The growing adoption and utilization of the Xoft System further
validates that IORT is an attractive alternative for the treatment of
early stage breast cancer because of its compelling benefits to
patients,” said Ken Ferry, President and CEO of iCAD. “By offering IORT
with the Xoft System, hospitals are able to expand their comprehensive
breast care programs by providing appropriate patients with the option
to complete a full dose of radiation therapy in a single treatment.”
“The Xoft System provides patients with a treatment option that helps
mitigate the logistical burdens often associated with a traditional
course of radiation treatment,” said Barbara Schwartzberg, M.D.,
Director of Breast Services, Sarah Cannon/HealthONE, Rose Medical
Center. “IORT with the Xoft System delivers radiation directly into the
tumor cavity while the patient is still under anesthesia, minimizing
radiation exposure to surrounding healthy tissue. Because the treatment
is delivered in one dose, my patients are able to maintain their quality
of life and return to their jobs and families quickly.”
A post-market, prospective, multi-center, clinical
trial evaluating the safety, efficacy and cosmetic outcomes
associated with IORT for early-stage breast cancer with the Xoft System
is currently underway at hospitals across the U.S.
iCAD to Host Lunch Symposium during Miami Breast Cancer Conference
On
March 8, 2014, iCAD will host the Breast
IORT Symposium: Clinical and Practice Perspectives from 1:00
p.m. EST – 2:15 p.m. EST at the Fontainebleau Miami Beach Hotel during
the 31st Annual Miami Breast Cancer Conference taking place
March 6 – March 9, 2014. Leading breast cancer surgeons will present and
discuss their IORT clinical experience, which includes more than 400
patients. Topics will include IORT techniques, clinical advancements,
scientific evidence, case review and IORT study protocol. The event is
open to all conference attendees and the public. For more details or to
register, please visit: http://www.xoftinc.com/IORTsymposiumreg.html.
iCAD will also showcase the Xoft System during the Miami Breast Cancer
Conference at Booth #22.
About Xoft Axxent Electronic Brachytherapy System
The Xoft
System is an isotope-free radiation treatment cleared by the U.S. Food
and Drug Administration and CE marked in the EU for use anywhere in the
body, including for the treatment of early-stage breast cancer,
gynecological cancers and non-melanoma skin cancer. It utilizes a
proprietary miniaturized x-ray as the radiation source that delivers
precise treatment directly to cancerous areas while sparing healthy
tissue and organs. The Xoft System requires only minimal shielding and
therefore does not require room redesign or construction investment.
Minimal shielding also allows medical personnel to remain in the room
with the patient during treatment. The mobility of the Xoft System makes
it easy to treat patients at multiple locations and to easily store the
system when not in use. Xoft is a wholly owned subsidiary of iCAD, Inc.
For more information about Xoft visit www.xoftinc.com,
like us on Facebook
or follow us on Twitter at @xofticad.
About iCAD, Inc.
iCAD is an industry-leading provider of
advanced image analysis, workflow solutions and radiation therapy
solutions for the early identification and treatment of cancer. iCAD’s
Xoft System offers radiation treatment for early-stage breast cancer
that can be administered in the form of intraoperative radiation therapy
or accelerated partial breast irradiation. The Xoft System is also
cleared for the treatment of non-melanoma skin cancer and endometrial
cancer. iCAD offers a comprehensive range of high-performance,
upgradeable CAD solutions for mammography and advanced image analysis
and workflow solutions for Magnetic Resonance Imaging, for breast and
prostate cancers and Computed Tomography for colorectal cancer.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995:
Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve a number of known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or
achievements of the Company to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited
to, the Company’s significant losses and uncertainty of our ability to
achieve and sustain profitability, the ability to protect patents and
other proprietary rights, the ability to defend itself in litigation
matters, the Company’s customers’ ability to obtain appropriate
coverage, and reimbursement from third-party payors, for our products
and treatments,, the Company’s ability to create significant markets for
its newly developed products and treatments, the Company’s dependence on
a limited number of customers, the uncertainty of growth of the
Company’s product markets, the risk of impairment of the Company’s
goodwill or other intangible assets, the risks related to regulatory and
other legal requirements, the significant costs of extensive regulatory
compliance, the volatility of the Company’s operating and financial
results, the risks related to the Company’s existing and future debt
obligations, the possible technological obsolescence of the Company’s
products, the impact of supply and manufacturing constraints or
difficulties, competitive pressures and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”,
“likely”, and similar expressions identify forward-looking statements.
Readers are cautioned not to place undue reliance on those
forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any
updates to any information contained in this release. For additional
disclosure regarding these and other risks faced by iCAD, please see the
disclosure contained in our public filings with the Securities and
Exchange Commission, available on the Investors section of our website
at http://www.icadmed.com
and on the SEC’s website at http://www.sec.gov.
Copyright Business Wire 2014